New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 19, 2013
07:15 EDTBCLI, ATHX, NBS, PSTI, CUR, OSIRRRY Publications to host a summit
8th Annual New York Stem Cell Summit '13 is being held in New York on February 19.
News For OSIR;PSTI;ATHX;CUR;NBS;BCLI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 29, 2015
09:06 EDTPSTIOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Flextronics (FLEX), up 6%... Coach (COH), up 6.3%... Autoliv (ALV), up 4.3%... Dow Chemical (DOW), up 3.5%... Ford (F), up 0.8%. ALSO HIGHER: McDonald's (MCD), up 3% after announcing CEO change...Xencor (XNCR), up 19% after reporting results from two trials... Pluristem Therapeutics (PSTI), up 8% after providing update and outlook on trials and pipeline... Avon Products (AVP), up 2.3% after naming James Scully as CFO... Omeros (OMER), up 6% after 2.996M share spot secondary priced at $20.03. DOWN AFTER EARNINGS: Alibaba (BABA), down 8%... Qualcomm (QCOM), down 6.8%... Alexion (ALXN), down 1.1% after reporting fourth quarter results, fiscal 2015 guidance, and CEO appointment. ALSO LOWER: Yahoo (YHOO), down 7% following Alibaba earnings report... Venaxis (APPY), down 72% after its APPY1 Test was determined by the FDA to not meet the criteria for substantial equivalence.
January 26, 2015
16:38 EDTBCLIBrainStorm files to sell 3.94M shares of common stock for holders
Subscribe for More Information
16:37 EDTBCLIBrainStorm files to sell 3.86M shares for holders
07:06 EDTBCLIBrainStorm announces positive preclinical results of NurOwn
Subscribe for More Information
January 22, 2015
07:15 EDTATHXAthersys announces GBP 2M grant to support Phase 2a clinical study of MultiStem
Subscribe for More Information
January 20, 2015
07:33 EDTNBSNeoStem receives drug manufacture license for Irvine, CA facility
NeoStem announced that the State of California's Department of Public Health, Food and Drug Branch has completed its review of NeoStem's manufacturing and control processes at its Irvine, California cGMP facility for the production of eltrapuldencel-T and has issued NeoStem a manufacturing license permitting NeoStem to manufacture drugs from this facility, including the manufacture of eltrapuldencel-T for clinical trial use. Eltrapuldencel-T is the company's patient-specific targeted cancer immunotherapy under investigation for the treatment of Stage IV or recurrent Stage III metastatic melanoma.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use